加载中
NASDAQHealthcareBiotechnology
最新数据
US$0.841
+US$0.0025 · +0.30%
Creative Medical Technology Holdings, Inc., a biotechnology firm based in Phoenix, Arizona, specializes in advancing adult stem cell treatments. The company's core focus spans several medical fields, including immunology, urology, orthopedics, and neurology. Among its therapeutic offerings are CaverStem, designed to address erectile dysfunction; FemCelz, which aims to restore genital sensitivity and alleviate dryness; StemSpine, developed to treat chronic lower back pain; ImmCelz, intended for stroke patients; and OvaStem, a solution for female infertility.
前收盘价
US$0.841
+US$0.0025 · +0.30%
盘中时间采用ET。市场数据可能有所延迟。
Creative Medical Technology Holdings, Inc., a biotechnology firm based in Phoenix, Arizona, specializes in advancing adult stem cell treatments. The company's core focus spans several medical fields, including immunology, urology, orthopedics, and neurology. Among its therapeutic offerings are CaverStem, designed to address erectile dysfunction; FemCelz, which aims to restore genital sensitivity and alleviate dryness; StemSpine, developed to treat chronic lower back pain; ImmCelz, intended for stroke patients; and OvaStem, a solution for female infertility.
日内区间
当前US$0.841
52周区间
当前US$0.841
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
43
合理估值
情绪
55
多空交织
风险
76
高风险
动量
18
强势下行
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Creative Medical Technology Holdings, Inc., a biotechnology firm based in Phoenix, Arizona, specializes in advancing adult stem cell treatments. The company's core focus spans several medical fields, including immunology, urology, orthopedics, and neurology. Among its therapeutic offerings are CaverStem, designed to address erectile dysfunction; FemCelz, which aims to restore genital sensitivity and alleviate dryness; StemSpine, developed to treat chronic lower back pain; ImmCelz, intended for stroke patients; and OvaStem, a solution for female infertility.
日内区间
当前US$0.841
52周区间
当前US$0.841
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 6000 USD | 1.1万 USD | 9000 USD | 8.86万 USD | 8.78万 USD |
| 销货成本 | 2194 USD | 4400 USD | 3600 USD | 2.85万 USD | 4.79万 USD |
| 毛利 | 3806 USD | 6600 USD | 5400 USD | 6.01万 USD | 3.98万 USD |
| 研究与开发 | 225.98万 USD | 240.08万 USD | 197.06万 USD | 626.89万 USD | 10.92万 USD |
| 销售、一般及管理费用 | 376.35万 USD | 323.92万 USD | 356.03万 USD | 394.35万 USD | 296.45万 USD |
| 营业费用 | 614.66万 USD | 575.05万 USD | 562.55万 USD | 1030.45万 USD | 316.58万 USD |
| 利息收入 | 14.78万 USD | 25.04万 USD | 33.36万 USD | 10.03万 USD | — |
| 利息支出 | — | — | — | — | 427.84万 USD |
| 折旧和摊销 | 12.33万 USD | 11.05万 USD | 9.46万 USD | 9.21万 USD | 9.21万 USD |
| 营业利润 | −614.28万 USD | −574.39万 USD | −562.01万 USD | −1024.44万 USD | −312.59万 USD |
| 净利润 | −599.5万 USD | −549.35万 USD | −528.66万 USD | −1014.4万 USD | 1921.18万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2023年6月12日 | 1:10 | — | — |
股票拆分 | 2021年11月10日 | 1:500 | — | — |
股票拆分 | 2020年2月3日 | 1:150 | — | — |
已生效 2023年6月12日
1:10
已生效 2021年11月10日
1:500
已生效 2020年2月3日
1:150
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
